Shawn Cross
Known title: Chief Financial OfficerCIK: 0001734779
Associated companies
Transaction History
| PCRX | ▲ Buy | Option Exercise | 12,941 | $213K | 4/23/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 12,941 | $326K | 4/23/2026 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 1,500 | $25K | 4/22/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,500 | $38K | 4/22/2026 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,845 | $47K | 4/21/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,845 | $71K | 4/21/2026 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 7,714 | $127K | 4/20/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 7,714 | $194K | 4/20/2026 | View on chart |
| PCRX | ▲ Buy | Grant | 49,091 | $0 | 2/11/2026 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 9,104 | $150K | 12/10/2025 | View on chart |
| PCRX | ▼ Sell | Open Market | 9,104 | $229K | 12/10/2025 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 15,896 | $261K | 12/9/2025 | View on chart |
| PCRX | ▼ Sell | Open Market | 15,896 | $398K | 12/9/2025 | View on chart |
| PCRX | ▼ Sell | Open Market | 12,060 | $266K | 11/10/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 6,690 | $143K | 10/31/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 75,000 | $0 | 11/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.